Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORA | P35398 | 2/20 | 0.61 |
| ▸ | RORC | P51449 | 2/20 | 0.61 |
| ▸ | RORB | Q92753 | 2/20 | 0.61 |
| ▸ | CNR2 | P34972 | 14/20 | 0.56 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | PGR | P06401 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14405501 | 0.82 | RORA (0.61) | RORARORCRORBCNR2PSEN1 | |
| SCHEMBL20760749 | 0.81 | RORA (0.61) | RORARORCRORBCNR2PSEN1 | |
| SCHEMBL3011106 | 0.81 | PGR (0.68) | RORARORCRORBCNR2PSEN1 | |
| SCHEMBL28304215 | 0.81 | PGR (0.68) | RORARORCRORBCNR2PSEN1 | |
| SCHEMBL28305156 | 0.81 | PGR (0.68) | RORARORCRORBCNR2PSEN1 | |
| SCHEMBL28304199 | 0.81 | PGR (0.68) | RORARORCRORBCNR2PSEN1 | |
| SCHEMBL4779301 | 0.81 | FABP4 (0.56) | — | |
| SCHEMBL21042574 | 0.81 | RORA (0.60) | RORARORCRORBCNR2PSEN1 | |
| SCHEMBL5795461 | 0.80 | PGR (0.70) | RORARORCRORBCNR2PSEN1 | |
| Boric Acid SCHEMBL28519644 | 0.79 | CNR2 (0.58) | RORARORCRORBCNR2PSEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8283855-B2 | Method for synthesis of anthracene derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-10-09 | — | — | US | claimed |
| US-20110172441-A1 | METHOD FOR SYNTHESIS OF ANTHRACENE DERIVATIVE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2011-07-14 | — | — | US | claimed |
| US-8283855-B2 | Method for synthesis of anthracene derivative | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2012-10-09 | — | — | US | disclosed |
| US-20110172441-A1 | METHOD FOR SYNTHESIS OF ANTHRACENE DERIVATIVE | SEMICONDUCTOR ENERGY LABORATORY CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172441-A1 | METHOD FOR SYNTHESIS OF ANTHRACENE DERIVATIVE | CYP1A1, AHR, CYP2C9 | RORA 834/4885RORC 1153/4885RORB 1087/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.